Amneal Pharmaceuticals (AMRX) reported $702.47 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 13.3%. EPS of $0.16 for the same period compares to $0.19 a year ago. The reported revenue represents a surprise of +1.27% over the Zacks Consensus Estimate of $693.68 million. With the consensus EPS estimate being $0.13, the EPS surprise was +23.08%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they c ...

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.19 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 23.08%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.14 per share when it actually produced earnings of $0.16, delivering a surprise of 14.29%. Over the last fou ...

Revenue Performance - Q3 2024 net revenue was $702 million, a 13% increase compared to $620 million in Q3 2023[3] - Net revenue for Q3 2024 increased to $702.5 million, up 13.3% from $620.0 million in Q3 2023[17] - Generics net revenue increased 9% driven by strong performance of new product launches and biosimilars[3] - Specialty net revenue increased 19% driven by promoted products in neurology and endocrinology, including the recent launches of CREXONT and ONGENTYS for Parkinson's disease[3] - AvKARE net revenue increased 21% driven by growth across its distribution and government label sales channels[3] - Generics segment net revenue for Q3 2024 was $427.3 million, a 9.3% increase from $390.9 million in Q3 2023[31] - Specialty segment net revenue for Q3 2024 was $115.6 million, an 18.8% increase from $97.3 million in Q3 2023[38] - Generics segment nine-month net revenue for 2024 was $1.25 billion, a 12.4% increase from $1.11 billion in 2023[34] - Specialty segment nine-month net revenue for 2024 was $324.9 million, a 13.6% increase from $285.9 million in 2023[40] - Net revenue for the three months ended September 30, 2024 was $159.485 million, compared to $131.879 million in the same period in 2023[42] - Net revenue for the nine months ended September 30, 2024 was $492.559 million, compared to $382.286 million in the same period in 2023[44] Profitability and Margins - Gross profit for Q3 2024 rose to $269.6 million, a 15.9% increase from $232.5 million in Q3 2023[17] - Operating income for Q3 2024 grew to $88.8 million, up 17.4% from $75.6 million in Q3 2023[17] - Generics segment gross margin improved to 44.3% in Q3 2024 from 43.0% in Q3 2023[31] - Specialty segment gross margin increased to 80.2% in Q3 2024 from 79.7% in Q3 2023[38] - Gross margin for the three months ended September 30, 2024 was 17.7%, down from 19.9% in the same period in 2023[42] - Gross margin for the nine months ended September 30, 2024 was 16.3%, down from 16.7% in the same period in 2023[44] - Operating income for the three months ended September 30, 2024 was $16.659 million, up from $15.533 million in the same period in 2023[42] - Operating income for the nine months ended September 30, 2024 was $46.078 million, up from $34.001 million in the same period in 2023[44] Segment Performance - Generics segment operating income for Q3 2024 was $102.2 million, a 3.9% decrease from $106.3 million in Q3 2023[31] - Specialty segment operating income for Q3 2024 was $61.2 million, a 24.5% increase from $49.2 million in Q3 2023[38] - Generics segment nine-month operating income for 2024 was $315.5 million, a 10.2% increase from $286.2 million in 2023[34] - Specialty segment nine-month operating income for 2024 was $171.5 million, a 19.7% increase from $143.3 million in 2023[40] Financial Position - Total current assets as of September 30, 2024, increased to $1.51 billion from $1.38 billion as of December 31, 2023[19] - Long-term debt decreased to $2.17 billion as of September 30, 2024, from $2.39 billion as of December 31, 2023[19] - Trade accounts receivable, net, increased to $748.1 million as of September 30, 2024, from $613.7 million as of December 31, 2023[19] - Total liabilities as of September 30, 2024, were $3.46 billion, slightly down from $3.47 billion as of December 31, 2023[19] - Cash and cash equivalents decreased to $74.0 million as of September 30, 2024, from $91.5 million as of December 31, 2023[19] Earnings and Losses - Diluted loss per share in Q3 2024 was $0.00 compared to diluted income per share of $0.06 in Q3 2023[5] - Adjusted diluted EPS in Q3 2024 was $0.16 compared to $0.19 in Q3 2023[5] - Net loss attributable to Amneal Pharmaceuticals for Q3 2024 was $0.2 million, compared to a net income of $9.7 million in Q3 2023[17] - Net loss for the nine months ended September 30, 2024 was $53.1 million, compared to a net income of $44.6 million in the same period of 2023[21] - Adjusted diluted earnings per share for the nine months ended September 30, 2024 was $0.46, compared to $0.50 in the same period of 2023[24] Research and Development - Research and development expenses for Q3 2024 increased to $61.1 million, up 47.7% from $41.4 million in Q3 2023[17] - The company launched CREXONT for the treatment of Parkinson's disease and announced a collaboration with Metsera, Inc. for next-generation medicines for obesity and metabolic diseases[2] - The company expanded its pipeline by in-licensing a new high-value biosimilar[2] Adjusted EBITDA and Cash Flow - Adjusted EBITDA in Q3 2024 was $158 million, a 2% increase compared to Q3 2023, partially offset by a $20 million R&D milestone payment[4] - Adjusted EBITDA for the nine months ended September 30, 2024 was $472.2 million, an increase from $416.1 million in the same period of 2023[23] - Net cash provided by operating activities for the nine months ended September 30, 2024 was $177.0 million, a decrease from $209.8 million in the same period of 2023[21] Expenses and Adjustments - Depreciation and amortization expenses for the nine months ended September 30, 2024 were $170.1 million, slightly lower than $172.5 million in the same period of 2023[21] - Inventory provision for the nine months ended September 30, 2024 was $63.6 million, an increase from $56.6 million in the same period of 2023[21] - Charges related to legal matters for the nine months ended September 30, 2024 were $94.9 million, primarily associated with a nationwide opioid settlement[27] - Non-GAAP effective tax rate for the nine months ended September 30, 2024 was 24.7%, compared to 21.6% in the same period of 2023[28] - System implementation expenses for the nine months ended September 30, 2024 were $2.0 million, primarily for integrating acquired businesses[28] - Adjustments for the three months ended September 30, 2024 included $3.5 million in amortization expense[43] - Adjustments for the nine months ended September 30, 2024 included $10.6 million in amortization expense[45] Full-Year Guidance - Full-year 2024 guidance includes net revenue of $2.70 billion to $2.80 billion, adjusted EBITDA of $610 million to $630 million, and adjusted diluted EPS of $0.57 to $0.63[6]

Wall Street analysts expect Amneal Pharmaceuticals (AMRX) to post quarterly earnings of $0.13 per share in its upcoming report, which indicates a year-over-year decline of 31.6%. Revenues are expected to be $693.68 million, up 11.9% from the year-ago quarter.The current level reflects a downward revision of 3.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Be ...

Efficiency level measures a company's capability to transform available input into output and is often considered an important parameter for gauging its potential to make profits. A company with a high-efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance. However, at times, it becomes difficult to measure the efficiency level of a company. This is why one must consider the popular efficiency ratios listed below while selecting stocks. T ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Amneal Pharmaceuticals (AMRX) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on November 8, 2024, might help the stock move higher if these key numbers are ...

The S&P 500 jumped to fresh highs on Monday and the Nasdaq's climb put it on the cusp of its July peaks. The strong start to the week came after JPMorgan and other Wall Street giants kicked off earnings season on a high note. See the Zacks Earnings Calendar to stay ahead of market-making news. The upbeat start to earnings season helped raise the outlook for total S&P 500 earnings growth. More volatility could come down the road, especially with the election around the corner. Still, the bullish backdrop of ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Amneal Pharmaceuticals (AMRX) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Amneal Pharmaceuticals is one of 1025 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank gau ...

Shares of Amneal Pharmaceuticals (AMRX) , a commercial-stage company marketing generics as well as specialty pharmaceutical products for several therapeutic areas, including neurology and endocrinology, have soared 29.3% in the past month after the company announced back-to-back regulatory approvals.Amneal Gets FDA Nod for Parkinson’s Disease DrugIn August 2024, the FDA approved Amneal’s IPX203, a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release (IR) granules and ex ...

Momentum investing is essentially an exception to the idea of "buying low and selling high." Investors following this style of investing are usually not interested in betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potenti ...